Clinical Trial Update: Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial of VS-4718 in combination with nab-paclitaxel and gemcitabine in pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• VS-4718

Snippet

Sponsor: Verastem, Inc. | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED